Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rhIL-2 for recently diagnosed type 1 diabetes
NL-OMON47333Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aldesleukin in diabetes mellitus type 1 (T1D), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Preservation of residual pancreatic beta-cell function and Optimal administration regimen selection. Started Feb 2018; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON47333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47333.